Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

Brotherton, Julia; Fridman, Masha; May, Cathryn L; Chappell, Genevieve; Saville, A Marion; Gertig, Dorota M.

doi:10.1016/s0140-6736(11)60551-5

Cited by 440 publications

(302 citation statements)

References 17 publications

Supporting

Mentioning

285

Contrasting

Unclassified

Order By: Relevance

“…24 Our observed safety findings are also similar to that of other studies, whereby vaccine recipients have higher rates of injection site pain, erythema and swelling, but similar rates of systemic AEs. 32 Given the high vaccine efficacy seen in the clinical trials, and the fact that in the 8 y since its original licensure, the qHPV vaccine has been shown to be highly effective at the population level, with marked reductions in the prevalence of HPV vaccine-type related infection and disease in many countries, [33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50] our findings suggest the vaccine should be equally effective in sub-Saharan African women.…”

mentioning

confidence: 99%

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

Mugo

Ansah

Marino

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

mentioning

confidence: 99%

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

Mugo

Ansah

Marino

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…6 Data from Australia, the United States and the United Kingdom have shown that the vaccine is effective, with population level reductions in rates of genital warts, HPV and cervical cancer lesions. [7][8][9][10] Recent data from a populationbased study in the US, where HPV vaccine uptake has been <40%, found a reduction in HPV vaccine-type prevalence from 11.5% to 5.1% pre-and post-vaccine, respectively. 11 In Canada, between 2007 and 2009 all provinces and territories launched school-based HPV vaccine programs.…”

mentioning

confidence: 99%

Reduction in cervical intraepithelial neoplasia in young women inBritishColumbia after introduction of theHPVvaccine: An ecological analysis

Naus

Money

Dobson

et al. 2015

Intl Journal of Cancer

View full text Add to dashboard Cite

We report on the rates of cervical intraepithelial neoplasia (CIN) in young women aged 15-22 years of age in British Columbia before and after the introduction of an HPV vaccine program. Rates of cervical intraepithelial neoplasia (CIN) 21 for each age stratum (15)(16)(17)(18)(19)(20)(21)(22) in the calendar years 2004-2012 for the province of British Columbia were obtained from the BC Cancer Agency's population-based cervical cancer program. Incidence rate ratios (IRR) of CIN21 were described and compared before and after HPV vaccine program introduction in cohorts born in vaccine eligible years, and in non-vaccine eligible years using piece-wise Poisson regression analysis, and adjusted for age. Between 2004 and 2012, rates of CIN2 and CIN21 in young women aged 15-22 years in the province of British Columbia have decreased overall. After the introduction of the HPV vaccine program, the age adjusted IRR for CIN21 for young women aged 15-17 years decreased significantly from 0.91 (95% CI: 0.86-0.98 p < 0.01) to 0.36 (95% CI: 0.18-0.73 p < 0.01). During the same time period, no similar reduction was found in young women 18-22 years. After introduction of HPV vaccine program, IRR for CIN21 in young women 15-17 was significantly reduced for CIN21 (0.14; 95% CI: 0.04-0.47; p < 0.01) and CIN2 (0.1; 95% CI: 0.02-0.54; p < 0.01). This ecological analysis shows a significant reduction in CIN21 lesions in young women aged 15-17 years in British Columbia after the introduction of the HPV vaccine in young women despite vaccine uptake levels below 70%.The HPV vaccine is one of the most important innovations in cancer prevention. Randomized trials have shown that both the quadrivalent and bivalent HPV vaccines are highly efficacious in preventing HPV infection, cervical dysplasia, anal dysplasia and in the case of the quadrivalent vaccine, genital warts.

show abstract

“…The state of Victoria has seen a decline of 0.38% in the incidence of high-grade (CIN2+) abnormalities in young women since vaccination began (number of new diagnoses within a 3-month period per 100 women tested) 10 . Perhaps more significantly, data for 2010 also reveal CORBIS It is hoped that mass vaccination of girls will protect non-vaccinated groups, including men.…”

Section: Into the Real Worldmentioning

confidence: 99%

Clinical approval: Trials of an anticancer jab

Clayton¹

2012

Nature

View full text Add to dashboard Cite

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

Cited by 440 publications

References 17 publications

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

Reduction in cervical intraepithelial neoplasia in young women inBritishColumbia after introduction of theHPVvaccine: An ecological analysis

Clinical approval: Trials of an anticancer jab

Contact Info

Product

Resources

About